MedTrace Logo

Edinburgh Pain Assessment Tool (EPAT©) Study

NCT00595777 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1928

Last updated 2012-09-26

No results posted yet for this study

Summary

To determine if the institutionalisation of a regular systematic approach to the assessment of pain in inpatient cancer units using the Edinburgh Pain Assessment Tool (EPAT©) leads to better control of pain than that achieved by usual care.

Conditions

Interventions

BEHAVIORAL

EPAT© Educational Package

The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.

Sponsors & Collaborators

Principal Investigators

  • Marie Fallon · University of Edinburgh

  • Michael Sharpe · University of Edinburgh

  • Lesley Colvin · University of Edinburgh

  • Gordon Murray · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595777 on ClinicalTrials.gov